AHA Conference Repository

Showing 3 Abstracts.

Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg

Meeting name: Scientific Sessions 2025 , 2025 , New Orleans, Louisiana

Authors: Ruseva Aleksandrina, Bassan Matthew, Du Ella, Fabricatore Anthony, O Hartaigh Briain, Michalak Wojciech, Ramasubramanian Ramya, Shen Pangsibo, Song Jinlin, Zhao Zhenxiang, Lopez-jimenez Francisco

Keywords: Obesity

Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)

Meeting name: Scientific Sessions 2025 , 2025 , New Orleans, Louisiana

Authors: Smolderen Kim, Mena-hurtado Carlos, Divino Victoria, Zhao Zhenxiang, Chen Yan, Boland Joanna, Song Jinlin, O Hartaigh Briain, Iyer Prashanth, Knop Filip, Nanna Michael

Keywords: Heart failure, Obesity, Cardiovascular Risk, Outcomes

Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)

Meeting name: Scientific Sessions 2025 , 2025 , New Orleans, Louisiana

Authors: Smolderen Kim, Mena-hurtado Carlos, Divino Victoria, Zhao Zhenxiang, Chen Yan, Boland Joanna, Song Jinlin, O Hartaigh Briain, Traina Andrea, Ozer Kerem, Knop Filip, Nanna Michael

Keywords: Cardiovascular Risk, Outcomes, Obesity, Arteriosclerosis

American Heart Association

Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg

Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)